# A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

> **NCT02000700** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 17 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Canagliflozin 100 mg
- **DRUG:** Canagliflozin 50 mg
- **DRUG:** Canagliflozin 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02000700
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2017-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02000700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02000700, "A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02000700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*